Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : °øÁö»çÇ×
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]¿µ±¹ ¾à±¹, °Ç°­ »ýȰ ¼¾ÅÍ·Î ¹ßµ¸¿ò
³»   ¿ë

¿µ±¹ ¾à±¹, °Ç°­ »ýȰ ¼¾ÅÍ·Î ¹ßµ¸¿ò

±¹³»¿Ü »ç·Ê°íÂûÀ» ÅëÇÑ Ä¿¹Â´ÏƼ Äɾ¼­ÀÇ Áö¿ª¾à±¹ ¹× ¾à»ç ¿ªÇÒ Å½»ö 4

2020-01-28 06:00:42 ÇÑ»óÀÎ ±âÀÚ ÇÑ»óÀÎ ±âÀÚ hsicam@kpanews.co.kr

 ¿µ±¹ÀÇ »çȸº¸Àå ¼­ºñ½º 
 V. ÀÏÂ÷ÀÇ·á ³×Æ®¿öÅ©, °Ç°­»ýȰ ¾à±¹ 


ÀÏÂ÷ÀÇ·á ³×Æ®¿öÅ©(Primary Care Network, PCN)¿Í ¾à»çÀÇ ¿ªÇÒ 
2018~19 °èȹ¾È¿¡¼­ NHS´Â 2019³â ¸»±îÁö PCNÀÌ Àü±¹À» Æ÷°ýÇÒ ¼ö ÀÖµµ·Ï Á¦¾ÈÇϰí ÀÖ´Ù. ¿©±â¼­ Á¦¾ÈµÈ PCNÀº NHS ³»¿¡¼­ ±×µ¿¾È ºÐ¸®µÈ °³³äÀ¸·Î Ãë±ÞµÇ¾î¿Â ÀÏÂ÷ÀÇ·á(Primary Care)¿Í Ä¿¹Â´ÏƼ ÄÉ ¾î(Community Care) »çÀÌÀÇ °æ°è¸¦ Çã¹°°í ÅëÇյȠ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ´Ù.14) 
PCNÀº 2019³â 6¿ù ±âÁØ ¿µ±¹ ³» ¾à 1,000°³ÀÇ ³×Æ®¿öÅ©°¡ ÀÖ°í ÀϹݠÀûÀ¸·Î 3¸¸¿¡¼­ 5¸¸ ¸íÀÇ Áö¿ªÀα¸¸¦ ´ë»óÀ¸·Î ÇÑ´Ù. ÀÌ·¯ÇÑ Ä¿¹Â´ÏƼµé Àº °³ÀΠ¸ÂÃã¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖÀ» Á¤µµ·Î ±Ô¸ð°¡ ÀÛÀº Æ¯Â¡À» °¡Áø´Ù. 
GP°¡ PCNÀ» ¼±µµÇϴ ¿ªÇÒÀ» ´ã´çÇϹǷΠ¸ðµç PCNÀÇ Çٽɠ±â´ÉÀº ¹Ýµå½Ã GP°¡ ´ã´çÇÏ°Ô ÇØ¾ß ÇÑ´Ù. ÇÏÁö¸¸ PCNÀÇ °³³äÀº GP¸¸ÀÇ ¿ªÇÒ º¸´Ù ±¤¹üÀ§Çϸç Áö¿ª¾à±¹, °Ë¾È»ç, Ä¡°úÀÇ·á Á¦°øÀÚ, »çȸº¹Áö»ç, ÀÚ ¿øºÀ»çÀÚ, Áö¿ª¼­ºñ½º Á¦°øÀÚ ±×¸®°í Áö¹æÁ¤ºÎµéÀÇ ¿ªÇÒµµ PCN¿¡ Æ÷ ÇԵŠÀÖ´Ù.15) 
PCN¿¡ Âü¿©Çϴ Áö¿ª¾à±¹µéÀº °¡Ä¡±â¹Ý ¼ö°¡Á¦µµ(Quality Payment Scheme, QPS)¸¦ ÅëÇØ ¼ö°¡¸¦ Á¦°ø¹Þ°í ÀÖ´Ù. QPS´Â Æ¯Á¤ °¡Ä¡ ±âÁØ¿¡ ºÎÇÕÇÏ¿© Áö¿ª¾à±¹ÀÌ ÃëµæÇÑ Á¡¼ö¿¡ µû¶ó º¸»óÀ» Á¦°øÇϸç 2019/20¿¡ ´Â Á¡¼ö ´ç ÃÖ´ë 128ÆÄ¿îµå(ÇÑÈ­ ¾à 20¸¸¿ø)ºÎÅÍ ÃÖ¼Ò 64ÆÄ¿îµå(ÇÑÈ­ ¾à 10¸¸¿ø)ÀÇ ±Ý¾×ÀÌ Á¦°øµÉ ¿¹Á¤ÀÌ´Ù. PCNÀÇ °æ¿ì PCN Lead´Â 22.5 Á¡, ±× ¿Ü(non-PCN lead)´Â 12.5Á¡À» ¹ÞÀ» ¼ö Àִµ¥ PCN Lead´Â Áö¿ª ´ÜÀ§ ³»¿¡¼­ PCN¿¡ Âü¿©Çϴ ¾à±¹µéÀÇ ´ëÇ¥·Î ÀÇ»ç¼ÒÅëÀÇ Åë·Î ¿ªÇÒÀ» ´ã´çÇÑ´Ù.16) 
PCN¿¡¼­ ÀÓ»ó¾à»ç(Clinical pharmacists)µéÀº ¾à¹°°ËÅä, ¾à¹°Ä¡·á ÃÖÀûÈ­, ¾ÈÀüº¸Àå, Ç×»ýÁ¦ °ü¸®, °¡Á¤°£È£ Áö¿ø, Áø·á¼Ò ¿î¿µ µîÀÇ ¿ªÇÒÀ» ¸Ã°í, Áö¿ª¾à±¹ ¾à»çµéÀº ºñ±³Àû ½É°¢ÇÏÁö ¾ÊÀº Áúº´Ä¡·á³ª ÀÀ±Þóġ, ÀÇ ¾àǰÀÇ ¾ÈÀü¼º°ú È¿°úÇâ»ó, ¿¹¹æ¼­ºñ½º Á¦°øÀÇ ¿ªÇÒÀ» ´ã´çÇÑ´Ù.17) 

°Ç°­»ýȰ¾à±¹(Healthy Living Pharmacy, HLP) 
¿µ±¹Àº HLP¸¦ ÅëÇØ¼­ Áö¿ª¾à±¹ÀÌ ÀÌÀüÀÇ ÀǾàǰ °ø±ÞÀÚ ¿ªÇÒ¿¡¼­ ¹þ¾î³ª °Ç°­»ýȰ¼¾ÅͷΠ¹ßÀüÇØ ÀÚ°¡ Ä¡·á¿ä¹ý°ú °Ç°­»ýȰ½ÇõÀ» Áö¼Ó ÇÒ ¼ö Àִ ¹æ¹ýÀ» ¾Ë·ÁÁÖ°í Ãß°¡ÀûÀ¸·Î Ã³¹æ ÀǾàǰÀÇ ¾ÈÀüÇÑ »ç¿ë¹ý À» Á¦½ÃÇϵµ·Ï Çϰí ÀÖ´Ù.18) 
HLPÀÇ ´Ü°èº°·Î Á¦°øÇϴ ¼­ºñ½º´Â <Ç¥ 3>°ú °°´Ù. 2019³â 2¿ù±îÁö ¿µ±¹ ³» 9,535°³ÀÇ ¾à±¹µéÀÌ HLP Level 1À» ÀÎÁõ¹Þ¾ÒÀ¸¸ç 2020³â 4¿ù ±îÁö ¸ðµç ¾à±¹µéÀº Level 1ÀÇ ÀÎÁõÀ» ¹Þ¾Æ¾ß ÇÒ Àǹ«°¡ ¿ä±¸µÈ´Ù. 19) 


VI. ³ª°¡¸ç 
º» ±Û¿¡¼­´Â ¿ì¸®³ª¶ó¿Í ÀϺ», È£ÁÖ ¹× ¿µ±¹ÀÇ Ä¿¹Â´ÏƼ ÄɾîÀÇ µîÀå ¹è°æ°ú ÁÖ¿ä Á¦µµ¸¦ ¼Ò°³Ç졒ʡ¢ Á¦µµÀǠƯÀÌÁ¡ ¹× Áö¿ª¾à±¹°ú ¾à»çÀÇ ¿ªÇÒÀ» °íÂûÇß´Ù. ¿ì¸®³ª¶óÀÇ °æ¿ì Ä¿¹Â´ÏƼ Äɾî´Â Áö¿ª»çȸ ÅëÇÕ µ¹ º½ Ã¼°è¸¦ ±¸ÃàÇÒ ¸ñÀûÀ¸·Î ¼±µµ »ç¾÷ÀÌ ½ÃÇàÁß¿¡ ÀÖÀ¸¸ç, ÀϺ»Àº Áö¿ª Æ÷°ýÄɾî½Ã½ºÅÛÀ» ¿î¿µÇϰí Àִµ¥, Æ¯È÷ ´Ü°ñ¾à»çÁ¦µµ¸¦ ¿î¿µÇØ Áö¿ª ¾à±¹À¸·Î ÇÏ¿©±Ý ±ÞÁõÇϴ ³ëÀÎÀα¸¸¦ ´ë»óÀ¸·Î ÀûÀýÇÑ ¾à¹°º¹¿ëÀ» °ü¸®Çϴ ¿ªÇÒÀ» ´ã´çÇϰԠÇϰí ÀÖ´Ù. 
È£ÁÖÀÇ °æ¿ì´Â, ¾à»ç°¡ ÀϹÝÀǿ͠Çù·ÂÇÏ¿© °¡Á¤ ¹æ¹®¿¡¼­ ¾à¹° ¿ä¹ýÀ» Á¾ÇÕÀûÀ¸·Î °ËÅäÇϰí ÀÇ»ç¿Í ÇÕÀÇÇÏ¿© ¾à¹° °ü¸® °èȹÀ» °³¹ßÇ졒ʡèȹÀÇ ÀÌÇà¿¡ Á߽ɠ¿ªÇÒÀ» ¼öÇàÇϰԠÇϰí ÀÖ¾ú´Ù. 
¿µ±¹Àº ÀÏÂ÷ÀÇ·á ³×Æ®¿öÅ© ±¸¼º ¹× °Ç°­»ýȰ¾à±¹ÀÇ ¿î¿µ¿¡ ÀÖ¾î Áö¿ª ¾à±¹ÀÌ ÀÌÀüÀÇ ÀǾàǰ °ø±ÞÀÚ ¿ªÇÒ¿¡¼­ ¹þ¾î³ª °Ç°­»ýȰ¼¾ÅͷΠ¹ßÀüÇØ ÀÚ°¡ Ä¡·á¿ä¹ý°ú °Ç°­»ýȰ½ÇõÀ» Áö¼ÓÇÒ ¼ö Àִ ¹æ¹ýÀ» ¾Ë·ÁÁÖ°í Ãß°¡ÀûÀ¸·Î Ã³¹æ ÀǾàǰÀÇ ¾ÈÀüÇÑ »ç¿ë¹ýÀ» Á¦½ÃÇϴ ±â´ÉÀ» ´ã´çÇϵµ·Ï Çϰí ÀÖ´Ù. 
À̸¦ Á¾ÇÕÇØº¸¸é, º»°í¿¡¼­ »ìÆìº» 3°³±¹Àº Ä¿¹Â´ÏƼ ÄɾîÀÇ ½ÃÇà¿¡ À־¸°ÇÀÇ·á°ø±ÞÀ» ´ã´çÇϴ ¿©·¯ Àü¹®Á÷Á¾ÀÇ ÆÀ¿öũȰµ¿À» Çٽɠ°³³äÀ¸·Î ¼³Á¤Çϰí ÀÖ¾úÀ¸¸ç À̠Ȱµ¿¿¡¼­ Áö¿ª¾à±¹°ú ¾à»ç·Î ÇÏ¿©±Ý Áö¿ª»çȸ °ÅÁÖ¹ÎÀÇ Æ÷°ýÀûÀΠ°Ç°­°ü¸®¸¦ À§ÇÑ ÇٽɿªÇÒÀ» ´ã´çÇϰԠÇϰí ÀÖÀ½À» ¾Ë ¼ö ÀÖ¾ú´Ù. 


14) PCN Development Support - Guidance and Prospectus, NHS, 2019 
15) Primary care networks: A briefing for pharmacy teams, Primary Care Pharmacy Association (PCPA), June 2019 
16) Pharmacy Quality Scheme Guidance 2019/20, NHS England and NHS Improvement, 2019 
17) Guidance for Local Pharmaceutical Committees How to help contractors get involved with Primary Care Networks, NHS, 2019 
18) Evaluation of Managing Healthy Living Pharmacy for the Future, NHS 
19) PSNC, Healthy Living Pharmacies, Accessed 12/12/19 https://psnc.org.uk/services-commissioning/locally-commissioned-services/healthy-living-pharmacies/


 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
168 û³â¾à»ç¿Í ¾à´ë»ýÀ» À§ÇÑ Ä¿¸®¾î °³¹ß °¡À̵åºÏ ÃÖÀ±Á¤ 2022-02-14 2540
167 2020³â ±âºÎ±Ý ¸ðÁý ¹× ÁöÃâ ¸í¼¼¼­ ÀÌÁö¿¬ 2021-05-10 1486
166 [ȯÀÚ¾ÈÀü º¸°íÇнÀ ½Ã½ºÅÛ] '¾à±¹ ¾àÁ¦¾÷¹« °ü¸®Áöħ ¾È³»' °Ô½Ã ±èÁøÀÌ 2020-06-25 3602
165 2021 ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¿¬±¸¿ø ä¿ë °ø°í °ü¸®ÀÚ 2020-03-12 6739
164 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_Á¶±â´ëÀÀü°è¿¡ ÃÖÀûÈ­µÈ ¡®¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛ¡¯ ±è¼±Èñ 2020-02-26 3591
163 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_Äڷγª19 ´ëÀÀ FIP ½Å±Ô °¡À̵å¶óÀÎ ±è¼±Èñ 2020-02-26 3172
162 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_¼¼°è ¾à±¹µéÀÇ °¨¿°¼º Áúȯ °¨½Ã ¹× ´ëÀÀ »ç·Ê ¼Ò°³ 1Æí ±è¼±Èñ 2020-02-12 2068
161 "¾à·á»ç¾÷ ³Ñ¾î Áö¿ª Á᫐ ¾à±¹ °Ç°­Çãºê ¿ªÇÒ Èû¾µ °Í" ±è¼±Èñ 2020-01-30 1668
160 "¾à±¹ '°Ç°­ÁõÁø Çãºê' ¹æÇâÀ¸·Î °¡¾ß"...·¹Áö½ºÆ®¸® ±¸Ãà º»°ÝÈ­ ±è¼±Èñ 2020-01-30 1478
159 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]¿µ±¹ ¾à±¹, °Ç°­ »ýȰ ¼¾ÅÍ·Î ¹ßµ¸¿ò ±è¼±Èñ 2020-01-30 1668
158 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]È£ÁÖ, ¹æ¹® ¾à·á µµÀÔÇØ ¾à¹° ¿ä¹ý ÇýÅà ±Ø´ëÈ­ ±è¼±Èñ 2020-01-30 1380
157 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]ÀϺ», ¡®´Ü°ñ¾à»ç-ÀçÅù湮¿Ï·á¡¯ È£Æò ¼Ó Ȱ¼ºÈ­ ±è¼±Èñ 2020-01-30 1472
156 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]±¹³»¿Ü »ç·Ê°íÂûÀ» ÅëÇÑ Ä¿¹Â´ÏƼ Äɾ¼­ÀÇ Áö¿ª¾à±¹ ¹× ¾à»ç ¿ªÇÒ Å½»ö 1 ±è¼±Èñ 2020-01-30 1372
155 [±â»ç]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, ÆÐ³Î¾à±¹ ¸ðÁý Ȱµ¿ Àü°³ ±è¼±Èñ 2019-11-13 1537
154 [±â»ç]¾à±¹¸¸ÀÇ Ã¼°èÀû Á¤Ã¥¼ö¸³À§ÇÑ ¾à±¹DB ±¸Ãà 'ù¹ß' ±è¼±Èñ 2019-11-13 1443

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»